{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T18:05:22Z","timestamp":1765908322643,"version":"3.48.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"This study is funded by the Hellenic Atherosclerosis Society"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-025-04427-0","type":"journal-article","created":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T04:23:08Z","timestamp":1758342188000},"page":"1243-1252","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["HDL cholesterol as an associate of prevalent coronary artery disease in heterozygous Familial hypercholesterolemia beyond LDL cholesterol"],"prefix":"10.1007","volume":"90","author":[{"given":"Christos V.","family":"Rizos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genovefa","family":"Kolovou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vana","family":"Kolovou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Liamis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Skoumas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loukianos","family":"Rallidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia","family":"Garoufi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Sfikas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios","family":"Penopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanouil","family":"Skalidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimon","family":"Stamatelopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasileios","family":"Kotsis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michalis","family":"Doumas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaia","family":"Lambadiari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Anagnostis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evgenia","family":"Mavrokefalou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amalia","family":"Boufidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasiliki","family":"Giannakopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Anastasiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ermioni","family":"Petkou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charalambos","family":"Vlachopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioanna","family":"Dima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fakas","family":"Georgios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos A.","family":"Papathanasiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achilleas","family":"Attilakos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charalambos","family":"Koumaras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Agapakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Zacharis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chrysoula","family":"Moustou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Antza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chrysoula","family":"Boutari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aikaterini","family":"Kountouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Mpellou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisavet","family":"Prodromiadou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Liberopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,20]]},"reference":[{"key":"4427_CR1","doi-asserted-by":"publisher","unstructured":"P. Fularski, J. Hajdys, G. Majchrowicz, M. Stabrawa, E. Mlynarska et al., Unveiling Familial Hypercholesterolemia-Review, cardiovascular complications, Lipid-Lowering treatment and its efficacy. Int. J. Mol. Sci. 25(3) (2024). https:\/\/doi.org\/10.3390\/ijms25031637","DOI":"10.3390\/ijms25031637"},{"issue":"16","key":"4427_CR2","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1093\/eurheartj\/ehac605","volume":"44","author":"A von Eckardstein","year":"2023","unstructured":"von A. Eckardstein, B.G. Nordestgaard, A.T. Remaley, A.L. Catapano, High-density lipoprotein revisited: biological functions and clinical relevance. Eur. Heart J. 44(16), 1394\u20131407 (2023). https:\/\/doi.org\/10.1093\/eurheartj\/ehac605","journal-title":"Eur. Heart J."},{"issue":"6","key":"4427_CR3","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/j.1365-2796.2004.01405.x","volume":"256","author":"AC Jansen","year":"2004","unstructured":"A.C. Jansen, van E.S. Aalst-Cohen, M.W. Tanck, M.D. Trip, P.J. Lansberg et al., The contribution of classical risk factors to cardiovascular disease in Familial hypercholesterolaemia: data in 2400 patients. J. Intern. Med. 256(6), 482\u2013490 (2004). https:\/\/doi.org\/10.1111\/j.1365-2796.2004.01405.x","journal-title":"J. Intern. Med."},{"issue":"6","key":"4427_CR4","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1053\/euhj.2000.2408","volume":"22","author":"JT Real","year":"2001","unstructured":"J.T. Real, F.J. Chaves, I. Martinez-Uso, A.B. Garcia-Garcia, J.F. Ascaso et al., Importance of HDL cholesterol levels and the total\/ HDL cholesterol ratio as a risk factor for coronary heart disease in molecularly defined heterozygous Familial hypercholesterolaemia. Eur. Heart J. 22(6), 465\u2013471 (2001). https:\/\/doi.org\/10.1053\/euhj.2000.2408","journal-title":"Eur. Heart J."},{"issue":"3","key":"4427_CR5","doi-asserted-by":"publisher","first-page":"e1003062","DOI":"10.1371\/journal.pmed.1003062","volume":"17","author":"TG Richardson","year":"2020","unstructured":"T.G. Richardson, E. Sanderson, T.M. Palmer, M. Ala-Korpela, B.A. Ference et al., Evaluating the relationship between Circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis. PLoS Med. 17(3), e1003062 (2020). https:\/\/doi.org\/10.1371\/journal.pmed.1003062","journal-title":"PLoS Med."},{"issue":"32","key":"4427_CR6","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1093\/eurheartj\/ehx163","volume":"38","author":"CM Madsen","year":"2017","unstructured":"C.M. Madsen, A. Varbo, B.G. Nordestgaard, Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur. Heart J. 38(32), 2478\u20132486 (2017). https:\/\/doi.org\/10.1093\/eurheartj\/ehx163","journal-title":"Eur. Heart J."},{"key":"4427_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2019.01.001","volume":"283","author":"P Barter","year":"2019","unstructured":"P. Barter, J. Genest, HDL cholesterol and ASCVD risk stratification, Debate Atherosclerosis. 283, 7\u201312 (2019). https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.01.001","journal-title":"Debate Atherosclerosis"},{"issue":"3","key":"4427_CR8","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/BF03401525","volume":"16","author":"CV Rizos","year":"2017","unstructured":"C.V. Rizos, V. Athyros, E. Bilianou, G. Chrousos, A. Garoufi et al., An insight into Familial hypercholesterolemia in greece: rationale and design of the Hellenic Familial hypercholesterolemia registry (HELLAS-FH). Horm. (Athens). 16(3), 306\u2013312 (2017). https:\/\/doi.org\/10.1007\/BF03401525","journal-title":"Horm. (Athens)"},{"key":"4427_CR9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ijcard.2021.10.024","volume":"345","author":"CV Rizos","year":"2021","unstructured":"C.V. Rizos, I. Skoumas, L. Rallidis, E. Skalidis, K. Tziomalos et al., LDL cholesterol target achievement in heterozygous Familial hypercholesterolemia patients according to 2019 ESC\/EAS lipid guidelines: implications for newer lipid-lowering treatments. Int. J. Cardiol. 345, 119\u2013124 (2021). https:\/\/doi.org\/10.1016\/j.ijcard.2021.10.024","journal-title":"Int. J. Cardiol."},{"issue":"1","key":"4427_CR10","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12944-020-01289-5","volume":"19","author":"CV Rizos","year":"2020","unstructured":"C.V. Rizos, M. Florentin, I. Skoumas, K. Tziomalos, L. Rallidis et al., Achieving low-density lipoprotein cholesterol targets as assessed by different methods in patients with Familial hypercholesterolemia: an analysis from the HELLAS-FH registry. Lipids Health Dis. 19(1), 114 (2020). https:\/\/doi.org\/10.1186\/s12944-020-01289-5","journal-title":"Lipids Health Dis."},{"issue":"45","key":"4427_CR11","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"BG Nordestgaard","year":"2013","unstructured":"B.G. Nordestgaard, M.J. Chapman, S.E. Humphries, H.N. Ginsberg, L. Masana et al., Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European atherosclerosis society. Eur. Heart J. 34(45), 3478\u20133490a (2013). https:\/\/doi.org\/10.1093\/eurheartj\/eht273","journal-title":"Eur. Heart J."},{"issue":"9","key":"4427_CR12","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.amjcard.2008.06.056","volume":"102","author":"F Civeira","year":"2008","unstructured":"F. Civeira, E. Ros, E. Jarauta, N. Plana, D. Zambon et al., Comparison of genetic versus clinical diagnosis in Familial hypercholesterolemia. Am. J. Cardiol. 102(9), 1187\u20131193 (2008). https:\/\/doi.org\/10.1016\/j.amjcard.2008.06.056","journal-title":"Am. J. Cardiol."},{"key":"4427_CR13","doi-asserted-by":"crossref","unstructured":"W.J. Youden, Index for rating diagnostic tests cancer 3(1), 32\u201335 (1950). https:\/\/doi.org\/10.1002\/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3"},{"issue":"2","key":"4427_CR14","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1161\/hq0202.104059","volume":"22","author":"MJ Veerkamp","year":"2002","unstructured":"M.J. Veerkamp, de J. Graaf, S.J. Bredie, J.C. Hendriks, P.N. Demacker et al., Diagnosis of Familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study. Arterioscler. Thromb. Vasc Biol. 22(2), 274\u2013282 (2002). https:\/\/doi.org\/10.1161\/hq0202.104059","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"issue":"4","key":"4427_CR15","first-page":"428","volume":"15","author":"PW Connelly","year":"1999","unstructured":"P.W. Connelly, A. Petrasovits, S. Stachenko, D.R. MacLean, J.A. Little et al., Prevalence of high plasma triglyceride combined with low HDL-C levels and its association with smoking, hypertension, obesity, diabetes, sedentariness and LDL-C levels in the Canadian population. Can. Heart Health Surv. Res. Group. Can. J. Cardiol. 15(4), 428\u2013433 (1999)","journal-title":"Can. Heart Health Surv. Res. Group. Can. J. Cardiol."},{"issue":"1","key":"4427_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1080\/13813455.2016.1195411","volume":"123","author":"AM Kaneva","year":"2017","unstructured":"A.M. Kaneva, N.N. Potolitsyna, E.R. Bojko, Usefulness of the LDL-C\/apoB ratio in the overall evaluation of atherogenicity of lipid profile. Arch. Physiol. Biochem. 123(1), 16\u201322 (2017). https:\/\/doi.org\/10.1080\/13813455.2016.1195411","journal-title":"Arch. Physiol. Biochem."},{"key":"4427_CR17","doi-asserted-by":"publisher","unstructured":"J. Vekic, A. Zeljkovic, A.F.G. Cicero, A. Janez, A.P. Stoian et al., Atherosclerosis development and progression: the role of atherogenic small. Dense LDL Med. (Kaunas). 58(2) (2022). https:\/\/doi.org\/10.3390\/medicina58020299","DOI":"10.3390\/medicina58020299"},{"issue":"2","key":"4427_CR18","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3906\/sag-1410-40","volume":"46","author":"E Taylan","year":"2016","unstructured":"E. Taylan, E.P. Tuncel, Distribution of LDL subgroups in patients with hyperlipidemia Turk. J. Med. Sci. 46(2), 374\u2013380 (2016). https:\/\/doi.org\/10.3906\/sag-1410-40","journal-title":"J. Med. Sci."},{"issue":"2","key":"4427_CR19","doi-asserted-by":"publisher","first-page":"e0298070","DOI":"10.1371\/journal.pone.0298070","volume":"19","author":"F Zhang","year":"2024","unstructured":"F. Zhang, Y. Zhang, J. Zhang, X. Wang, Y. Li et al., Small dense low density lipoprotein predominance in patients with type 2 diabetes mellitus using Mendelian randomization. PLoS One. 19(2), e0298070 (2024). https:\/\/doi.org\/10.1371\/journal.pone.0298070","journal-title":"PLoS One"},{"issue":"18","key":"4427_CR20","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1001\/jama.2009.1619","volume":"302","author":"Di E Angelantonio","year":"2009","unstructured":"Emerging Risk Factors Collaboration, Di E. Angelantonio, N. Sarwar, P. Perry, S. Kaptoge et al., Major lipids, apolipoproteins, and risk of vascular disease JAMA 302(18), 1993\u20132000 (2009). https:\/\/doi.org\/10.1001\/jama.2009.1619","journal-title":"JAMA"},{"key":"4427_CR21","doi-asserted-by":"publisher","unstructured":"B.F. Voight, G.M. Peloso, M. Orho-Melander, R. Frikke-Schmidt, M. Barbalic et al., Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study lancet 380(9841), 572\u2013580 (2012). https:\/\/doi.org\/10.1016\/S0140-6736(12)60312-2","DOI":"10.1016\/S0140-6736(12)60312-2"},{"issue":"9","key":"4427_CR22","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/eurheartj\/eht571","volume":"36","author":"MV Holmes","year":"2015","unstructured":"M.V. Holmes, F.W. Asselbergs, T.M. Palmer, F. Drenos, M.B. Lanktree et al., Mendelian randomization of blood lipids for coronary heart disease. Eur. Heart J. 36(9), 539\u2013550 (2015). https:\/\/doi.org\/10.1093\/eurheartj\/eht571","journal-title":"Eur. Heart J."},{"issue":"5","key":"4427_CR23","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/eurjpc\/zwab185","volume":"29","author":"L Perez de Isla","year":"2022","unstructured":"L. Perez de Isla, G.F. Watts, O. Muniz-Grijalvo, J.L. Diaz-Diaz, R. Alonso et al., A resilient type of Familial hypercholesterolaemia: case-control follow-up of genetically characterized older patients in the SAFEHEART cohort. Eur. J. Prev. Cardiol. 29(5), 795\u2013801 (2022). https:\/\/doi.org\/10.1093\/eurjpc\/zwab185","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"1","key":"4427_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jacl.2018.10.012","volume":"13","author":"LE Akioyamen","year":"2019","unstructured":"L.E. Akioyamen, J. Genest, A. Chu, H. Inibhunu, D.T. Ko et al., Risk factors for cardiovascular disease in heterozygous Familial hypercholesterolemia: A systematic review and meta-analysis. J. Clin. Lipidol. 13(1), 15\u201330 (2019). https:\/\/doi.org\/10.1016\/j.jacl.2018.10.012","journal-title":"J. Clin. Lipidol."},{"issue":"1","key":"4427_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jacl.2016.10.004","volume":"11","author":"M Paquette","year":"2017","unstructured":"M. Paquette, R. Dufour, A. Baass, The Montreal-FH-SCORE: A new score to predict cardiovascular events in Familial hypercholesterolemia. J. Clin. Lipidol. 11(1), 80\u201386 (2017). https:\/\/doi.org\/10.1016\/j.jacl.2016.10.004","journal-title":"J. Clin. Lipidol."},{"issue":"22","key":"4427_CR26","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1161\/CIRCULATIONAHA.116.024541","volume":"135","author":"L Perez de Isla","year":"2017","unstructured":"L. Perez de Isla, R. Alonso, N. Mata, C. Fernandez-Perez, O. Muniz et al., Predicting cardiovascular events in Familial hypercholesterolemia: the SAFEHEART registry (Spanish Familial hypercholesterolemia cohort study. Circulation. 135(22), 2133\u20132144 (2017). https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.024541","journal-title":"Circulation"},{"issue":"10","key":"4427_CR27","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1161\/ATVBAHA.121.316106","volume":"41","author":"M Paquette","year":"2021","unstructured":"M. Paquette, S. Bernard, B. Cariou, R.A. Hegele, J. Genest et al., Familial hypercholesterolemia-Risk-Score: A new score predicting cardiovascular events and cardiovascular mortality in Familial hypercholesterolemia. Arterioscler. Thromb. Vasc Biol. 41(10), 2632\u20132640 (2021). https:\/\/doi.org\/10.1161\/ATVBAHA.121.316106","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"key":"4427_CR28","doi-asserted-by":"publisher","unstructured":"P. Anagnostis, C.V. Rizos, G. Liamis, L. Rallidis, I. Skoumas et al., Exploring the correlation between triglyceride levels and atherosclerotic cardiovascular disease prevalence in adults with Familial hypercholesterolemia: insights from a cross-sectional analysis in the HELLAS-FH registry J clin lipidol Epub ahead of print (2025). https:\/\/doi.org\/10.1016\/j.jacl.2024.12.017","DOI":"10.1016\/j.jacl.2024.12.017"},{"issue":"5","key":"4427_CR29","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s11883-010-0091-x","volume":"12","author":"S Ragbir","year":"2010","unstructured":"S. Ragbir, J.A. Farmer, Dysfunctional high-density lipoprotein and atherosclerosis. Curr. Atheroscler Rep. 12(5), 343\u2013348 (2010). https:\/\/doi.org\/10.1007\/s11883-010-0091-x","journal-title":"Curr. Atheroscler Rep."},{"key":"4427_CR30","doi-asserted-by":"publisher","unstructured":"K.G. Lagos, T.D. Filippatos, V. Tsimihodimos, I.F. Gazi, C. Rizos et al., Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome lipids 44(1), 9\u201316 (2009). https:\/\/doi.org\/10.1007\/s11745-008-3251-9","DOI":"10.1007\/s11745-008-3251-9"},{"key":"4427_CR31","doi-asserted-by":"publisher","unstructured":"J. Pedro-Botet, E. Climent, D. Benaiges, Familial hypercholesterolemia: do HDL play a role?? Biomedicines 9(7)(2021). https:\/\/doi.org\/10.3390\/biomedicines9070810","DOI":"10.3390\/biomedicines9070810"},{"key":"4427_CR32","doi-asserted-by":"publisher","unstructured":"S. Ganjali, S. Hosseini, M. Rizzo, A. Kontush, A. Sahebkar, Capacity of HDL to efflux cellular cholesterol from Lipid-Loaded macrophages is reduced in patients with. Familial Hypercholesterolemia Metabolites. 13(2) (2023). https:\/\/doi.org\/10.3390\/metabo13020197","DOI":"10.3390\/metabo13020197"},{"issue":"7","key":"4427_CR33","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/eci.12643","volume":"46","author":"J Versmissen","year":"2016","unstructured":"J. Versmissen, R. Vongpromek, R. Yahya, van der J.B. Net, van L. Vark-van et al., Familial hypercholesterolaemia: cholesterol efflux and coronary disease. Eur. J. Clin. Invest. 46(7), 643\u2013650 (2016). https:\/\/doi.org\/10.1111\/eci.12643","journal-title":"Eur. J. Clin. Invest."},{"issue":"6","key":"4427_CR34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11883-021-00928-1","volume":"23","author":"JC Escola-Gil","year":"2021","unstructured":"J.C. Escola-Gil, N. Rotllan, J. Julve, F. Blanco-Vaca, Reverse cholesterol transport dysfunction is a feature of Familial hypercholesterolemia. Curr. Atheroscler Rep. 23(6), 29 (2021). https:\/\/doi.org\/10.1007\/s11883-021-00928-1","journal-title":"Curr. Atheroscler Rep."},{"issue":"1","key":"4427_CR35","doi-asserted-by":"publisher","first-page":"e14083","DOI":"10.1111\/eci.14083","volume":"54","author":"R Scicali","year":"2024","unstructured":"R. Scicali, G. Bosco, A. Scamporrino, Di S. Mauro, A. Filippello et al., Evaluation of high-density lipoprotein-bound long non-coding RNAs in subjects with Familial hypercholesterolaemia. Eur. J. Clin. Invest. 54(1), e14083 (2024). https:\/\/doi.org\/10.1111\/eci.14083","journal-title":"Eur. J. Clin. Invest."},{"key":"4427_CR36","doi-asserted-by":"publisher","unstructured":"M. Palumbo, A. Giammanco, F. Purrello, C. Pavanello, G. Mombelli et al., Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in Familial hypercholesterolemia subjects: a multi-lipid-center real-world evaluation. Front. Mol. Biosci. 9(925587) (2022). https:\/\/doi.org\/10.3389\/fmolb.2022.925587","DOI":"10.3389\/fmolb.2022.925587"},{"key":"4427_CR37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.amjcard.2021.11.041","volume":"167","author":"C Liu","year":"2022","unstructured":"C. Liu, D. Dhindsa, Z. Almuwaqqat, Y.V. Sun, A.A. Quyyumi, Very high high-Density lipoprotein cholesterol levels and cardiovascular mortality. Am. J. Cardiol. 167, 43\u201353 (2022). https:\/\/doi.org\/10.1016\/j.amjcard.2021.11.041","journal-title":"Am. J. Cardiol."},{"issue":"1","key":"4427_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.5551\/jat.13201","volume":"20","author":"F Sbrana","year":"2013","unstructured":"F. Sbrana, M. Puntoni, F. Bigazzi, P. Landi, T. Sampietro et al., High density lipoprotein cholesterol in coronary artery disease: when higher means later. J. Atheroscler Thromb. 20(1), 23\u201331 (2013). https:\/\/doi.org\/10.5551\/jat.13201","journal-title":"J. Atheroscler Thromb."},{"key":"4427_CR39","doi-asserted-by":"publisher","unstructured":"A.M. Bea, A. Gonzalez-Guerrero, A. Cenarro, I. Lamiquiz-Moneo, E. Climent et al., Association of HDL cholesterol with all-cause and cardiovascular mortality in primary hypercholesterolemia atherosclerosis 400(118617 (2025). https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.118617","DOI":"10.1016\/j.atherosclerosis.2024.118617"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04427-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04427-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04427-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T18:02:59Z","timestamp":1765908179000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04427-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,20]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4427"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04427-0","relation":{},"ISSN":["1559-0100"],"issn-type":[{"type":"electronic","value":"1559-0100"}],"subject":[],"published":{"date-parts":[[2025,9,20]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by all institutions\u2019 scientific committees.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board"}},{"value":"CVR\n                      ,\n                      VK\n                      ,\n                      GL\n                      ,\n                      AG\n                      ,\n                      GS\n                      ,\n                      PA\n                      ,\n                      GA\n                      ,\n                      EP\n                      ,\n                      ID\n                      ,\n                      FG\n                      ,\n                      KAP\n                      ,\n                      AA\n                      ,\n                      VK\n                      ,\n                      CK\n                      ,\n                      CM\n                      ,\n                      CA\n                      ,\n                      CB\n                      ,\n                      AK\n                      ,\n                      VG\n                      have nothing to declare.\n                      IS\n                      has given talks, received honoraria, and participated in clinical trials sponsored by MSD, AMGEN, SANOFI.\n                      LR\n                      has received research grants and honoraria from Amgen, Sanofi-Aventis, Viatris, Novartis, Vianex and Servier.\n                      GK\n                      has given talks, attended conferences and participated in trials sponsored by Amgen, Angelini, MSD, Lilly, Vianex and Sanofi and has also accepted travel support to conferences from Amgen, Sanofi and MSD.\n                      KT\n                      has participated in educational, research and advisory activities sponsored by AMGEN, ANGELINI, ASTRA-ZENECA, BAYER, BOEHRINGER-INGELHEIM, ELPEN, LILLY, MSD, MYLAN, NOVO NORDISK, SANOFI and VIANEX.\n                      ES\n                      has participated in educational and advisory activities sponsored by AstraZeneca, Medtronic, MSD, Sanofi and Servier.\n                      VK\n                      has given talks and attended conferences sponsored by AstraZeneca, MSD, Sanofi-Aventis, and Vianex.\n                      MD\n                      has given lectures for and participated in trials sponsored by Novo-Nordisc, Astra-Zeneca, Novartis, Eli-Lilly, Menarini, WinMedica, Innovis, Boehringer, Elpen, Viatris.\n                      KS\n                      has received honoraria from Amgen.\n                      VL\n                      has given lectures, attended conferences and participated in trials sponsored by Novo Nordisk, Sanofi-Aventis, Novartis, AstraZeneca, Boehringer-Ingelheim, MSD, GSK, Vianex, Elli Lilly, ELPEN, Mylan and Aegereon.\n                      AB\n                      has received honoraria from Vianex, Amarin and Sanofi. EL has participated in educational, research and advisory activities sponsored by AstraZeneca, MSD, Lilly, Bayer, Amgen, Sanofi, Boehringer-Ingelheim, Novartis, Novo Nordisk, Valeant and Servier.\n                      CV\n                      has received grants and fees for scientific activities from Amgen, Sanofi and MSD.\n                      DA\n                      has participated in research and advisory activities sponsored by Amgen, AstraZeneca, Servier Hellas.\n                      EM\n                      has given talks, attended conferences and participated in trials sponsored by Amgen, Ionis, Sanofi, MSD, Vianex, Novartis, Elpen, Phizer and Servier and has also accepted travel support to conferences from Amgen, Sanofi, Novartis, Vianex, Menarini and MSD.\n                      EZ\n                      has received honoraria for lectures from Amgen. Sanofi, MSD, and Astra-Zeneca.\n                      ENL\n                      has participated in educational, research and advisory activities sponsored by AstraZeneca, MSD, Lilly, Bayer, Amgen, Sanofi, Boehringer-Ingelheim, Novartis, Novo Nordisk, Valeant and Servier.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}